Drugs / LY03020
LY03020
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT07230652 | Aug → Dec 2025 overdue | Alzheimer disease, schizophrenia | Luye Pharma Group Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT07292233 | Jul → Aug 2025 overdue | Alzheimer disease, schizophrenia | Luye Pharma Group Ltd. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06556966 | Aug 2024 → Feb 2025 | Alzheimer disease, schizophrenia | Luye Pharma Group Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07396870 | Mar 2026 → Dec 2027 expected | schizophrenia | Luye Pharma Group Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY03020 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06556966 ↗ |
| Known as | LPM787000048 | “A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dosed Phase II Clinical Study to Evaluate the Efficacy and Safety of LPM787000048 Maleate...” NCT07396870 ↗ |
| Known as | LPM787000048 Maleate sustained-release tablet | “A Phase Ⅰ, Randomized, Double-blind, Placebo-controlled, Single Dose Ascending Study to Assess the Safety, Tolerability, and Pharmacokinetics of LPM787000048 Maleate...” NCT06556966 ↗ |
| Route | Oral | “The subjects will be required to orally take LY03020 or a placebo on an empty stomach upon waking on D1 (the day of medication administration).” NCT06556966 ↗ |